Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Bavencio“
Suchtreffer
Begriffe & Kennungen
Bavencio · 4.8 · Immune-mediated colitis In patients treated with avelumab as monotherapy, 1.5% (31/2 082) of patients develope
Eintrag öffnenBavencio · 4.8 · Immune-mediated endocrinopathies Thyroid disorders In patients treated with avelumab as monotherapy, 6.7% (140
Eintrag öffnenBavencio · 4.8 · Immune-mediated hepatitis In patients treated with avelumab as monotherapy, 1.0% (21/2 082) of patients develo
Eintrag öffnenBavencio · 4.8 · Immune-mediated myocarditis In patients treated with avelumab as monotherapy, immune-mediated myocarditis occu
Eintrag öffnenBavencio · 4.8 · Immune-mediated nephritis and renal dysfunction In patients treated with avelumab as monotherapy, immune-media
Eintrag öffnenBavencio · 4.8 · Immune-mediated pancreatitis In patients treated with avelumab as monotherapy, immune-mediated pancreatitis oc
Eintrag öffnenBavencio · 4.8 · Immune-mediated pneumonitis In patients treated with avelumab as monotherapy, 1.3% (28/2 082) of patients deve
Eintrag öffnenBavencio · 4.8 · Immune-mediated pneumonitis did not lead to discontinuation of avelumab in any patient. All 3 patients with im
Eintrag öffnenBavencio · 4.8 · In patients treated with avelumab in combination with axitinib, 2.7% (13/489) of patients developed immune-med
Eintrag öffnenBavencio · 4.8 · In patients treated with avelumab in combination with axitinib, 24.7% (121/489) of patients developed immune-m
Eintrag öffnenBavencio · 4.8 · In patients treated with avelumab in combination with axitinib, 6.3% (31/489) of patients developed immune-med
Eintrag öffnenBavencio · 4.8 · In patients treated with avelumab in combination with axitinib, Type 1 diabetes mellitus without an alternativ
Eintrag öffnenBavencio · 4.8 · In patients treated with avelumab in combination with axitinib, immune-mediated nephritis occurred in 0.4% (2/
Eintrag öffnenBavencio · 4.8 · In patients with ALT ≥ 3 times ULN (Grades 2-4, n=82), ALT resolved to Grades 0-1 in 92%.
Eintrag öffnenBavencio · 4.8 · Renal cell carcinoma
Eintrag öffnenBavencio · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenBavencio · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenBavencio · 4.8 · Summary of the safety profile
Eintrag öffnenBavencio · 4.8 · Table 2: Adverse reactions in patients treated with avelumab as monotherapy
Eintrag öffnenBavencio · 4.8 · Table 3: Adverse reactions in patients treated with avelumab in combination with axitinib
Eintrag öffnen